Clinical Trial Update: A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating TAK-676 in combination with pembrolizumab after radiation therapy across several cancers; the study completed and posted results on 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Head and Neck
• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• TAK-676

Snippet

Sponsor: Takeda | Conditions: Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2025-09-04